Eupraxia Pharmaceuticals Inc. (EPRX)
USD 3.19
(-3.33%)
USD 3.19
(-3.33%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.06 Million | -13.85 Million | -11.57 Million | -317.05 Thousand | -3.98 Million | -6.09 Million |
| Net Income | -28.73 Million | -17.15 Million | -18.17 Million | -3.13 Million | -5.53 Million | -9.68 Million |
| Depreciation & Amortization | 158.37 Thousand | 142.57 Thousand | 88.17 Thousand | 91.68 Thousand | 155.72 Thousand | 92.12 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 1.41 Million | 1.43 Million | 4.21 Million | 228.68 Thousand | 544.95 Thousand | - |
| Change in working capital | 5.44 Million | 1.52 Million | -167.15 Thousand | 1.22 Million | 371.8 Thousand | 804.35 Thousand |
| Other non-cash items | 2.48 Million | 1.69 Million | 6.7 Million | 1.11 Million | 1.22 Million | 3.03 Million |
| Investing Cash Flow | -74.72 Thousand | 6.41 Million | -11.42 Million | 19.32 Thousand | -1.46 Million | -103.86 Thousand |
| Investments in PPE | -74.72 Thousand | -227.48 Thousand | -341.28 Thousand | - | -7309.81 | -103.86 Thousand |
| Acquisitions | - | 228.69 | - | 63.81 Thousand | - | - |
| Investment purchases | - | -3.27 Million | -7.11 Million | - | - | - |
| Sales/Maturities of investments | - | 6.64 Million | - | - | - | - |
| Other Investing Activities | - | 13.63 Million | -3.96 Million | -44.49 Thousand | -1.45 Million | - |
| Financing Cash Flow | 21.39 Million | 9.97 Million | 39.46 Million | -491.87 Thousand | 5.7 Million | 3.87 Million |
| Debt repayment | -80.89 Thousand | -71.91 Thousand | -9.62 Million | -412.83 Thousand | -5.79 Million | -2.66 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 21.54 Million | 10.11 Million | 29.91 Million | - | - | 1.21 Million |
| Other Financing Activities | 28.03 Million | 14.81 Million | 37.93 Million | -235.94 Thousand | 3.01 Million | - |
| Accounts receivables | -105.61 Thousand | 228.73 Thousand | 150.91 Thousand | 571.18 Thousand | 104.31 Thousand | -153.67 Thousand |
| Accounts payables | 577.9 Thousand | 1.32 Million | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 5.55 Million | 1.3 Million | -318.07 Thousand | 653.34 Thousand | 267.48 Thousand | 958.03 Thousand |
| Cash at beginning of period | 18.24 Million | 16.51 Million | 117.83 Thousand | 891.52 Thousand | 602.92 Thousand | 3.18 Million |
| Cash at end of period | 19.24 Million | 18.24 Million | 16.51 Million | 117.83 Thousand | 891.52 Thousand | 602.92 Thousand |
| Capital Expenditure | -74.72 Thousand | -227.48 Thousand | -341.28 Thousand | - | -7309.81 | -103.86 Thousand |
| Effect of forex changes on cash | 821.39 Thousand | -507.39 Thousand | -81.62 Thousand | -143.00 | - | - |
| Net cash flow / Change in cash | 995.09 Thousand | 1.73 Million | 16.39 Million | -773.68 Thousand | 288.59 Thousand | -2.58 Million |
| Free Cash Flow | -21.13 Million | -14.07 Million | -11.91 Million | -317.05 Thousand | -3.99 Million | -6.19 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -6.06 Million | -6.01 Million | -28.73 Million | -4.35 Million | -4.64 Million | -5.9 Million |
| Depreciation & Amortization | 42.03 Thousand | 37.25 Thousand | 158.37 Thousand | 7818.00 | 36.73 Thousand | 37.1 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 1.47 Million | 213.13 Thousand | 1.41 Million | -72.3 Thousand | 481.91 Thousand | 685.23 Thousand |
| Change in working capital | -2.84 Million | 248.99 Thousand | 5.44 Million | 5.56 Million | 288.27 Thousand | 974.34 Thousand |
| Other non-cash items | 51.7 Thousand | -305.94 Thousand | 2.48 Million | -64.72 Thousand | -1.43 Million | 635.84 Thousand |
| Investing Cash Flow | 17.66 Thousand | -6758.67 | -74.72 Thousand | -41.17 Thousand | -9387.48 | -6452.38 |
| Investments in PPE | -10.84 Thousand | -6758.67 | -74.72 Thousand | -41.17 Thousand | -9387.48 | -6452.38 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 39.01 | - | - | - | - | - |
| Financing Cash Flow | -4.49 Million | 23.05 Million | 21.39 Million | -7.29 Million | 16.22 Million | 4.53 Million |
| Debt repayment | -4.49 Million | -20.45 Thousand | -80.89 Thousand | -900.00 | -19.73 Thousand | -19.95 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -512.35 | - | - |
| Common Stock Issuance | - | 23.08 Million | 21.54 Million | -5.64 Million | 16.25 Million | 4.57 Million |
| Other Financing Activities | - | 31.41 Thousand | 28.03 Million | -46.75 | 22.08 Thousand | 6072.83 |
| Accounts receivables | 18.70 | 17.12 Thousand | -105.61 Thousand | -165.24 | -17.52 Thousand | 36.88 Thousand |
| Accounts payables | - | - | 577.9 Thousand | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -1210.53 | 231.87 Thousand | 5.55 Million | 6615.34 | 305.8 Thousand | 937.45 Thousand |
| Cash at beginning of period | 35.9 Million | 24.44 Million | 18.24 Million | 33.2 Million | 14.4 Million | 13.93 Million |
| Cash at end of period | 23.31 Million | 35.87 Million | 19.24 Million | 19.34 Million | 24.44 Million | 14.4 Million |
| Capital Expenditure | -10.84 Thousand | -6758.67 | -74.72 Thousand | -41.17 Thousand | -9387.48 | -6452.38 |
| Effect of forex changes on cash | -397.62 Thousand | -460.75 Thousand | 821.39 Thousand | 818.14 Thousand | 38.56 Thousand | -80.38 Thousand |
| Net cash flow / Change in cash | -12.59 Million | 11.42 Million | 995.09 Thousand | -13.86 Million | 10.03 Million | 469.35 Thousand |
| Free Cash Flow | -7.72 Million | -6.09 Million | -21.13 Million | -919.82 Thousand | -5.85 Million | -4.3 Million |
GLB
000716
MCBS
TRU
ISS
002542